Aarhus University researchers demonstrated a prime-editing approach that corrected part of the disease-causing GATA2 deficiency defect directly in a patient’s own blood stem cells. The team reported an increase in normally functioning gene copies from roughly 50% to 70% after editing, alongside improvements in affected protein function. Prime editing differs from conventional CRISPR by avoiding double-stranded DNA breaks, which the researchers say may reduce unintended outcomes. The paper and accompanying reporting framed the work as a step toward therapies that target underlying genetic causes rather than downstream symptom control. For the field, the key implication is feasibility: correcting enough functional copies to improve cellular function, even without editing every allele. The work also sets expectations for translational development, emphasizing that the platform is not yet ready for clinical use beyond laboratory or preclinical stages.